Cerenis Therapeutics Completes Phase I Clinical Trial Of CER-002 For Treatment Of Cardiovascular Disease

Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, announced that it has completed a Phase I clinical trial for CER-002, one of the company’s lead product candidates. CER-002 is a peroxisome proliferator-activated receptor (PPAR) delta-specific agonist in development for the treatment of cardiovascular diseases.

More: continued here

Filed under: Cardiovascular on May 17th, 2008